Cargando…
Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors
The majority of patients with gastrointestinal stromal tumors (GIST) eventually become resistant with time due to secondary mutations in the driver receptor tyrosine kinase. Novel treatments that do not target these receptors may therefore be preferable. For the first time, we evaluated a tubulin in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381700/ https://www.ncbi.nlm.nih.gov/pubmed/32711367 http://dx.doi.org/10.1016/j.tranon.2020.100832 |
_version_ | 1783563098978779136 |
---|---|
author | Wang, Yannick Wozniak, Agnieszka Wellens, Jasmien Gebreyohannes, Yemarshet K. Guillén, Maria Jose Avilés, Pablo M. Debiec-Rychter, Maria Sciot, Raf Schöffski, Patrick |
author_facet | Wang, Yannick Wozniak, Agnieszka Wellens, Jasmien Gebreyohannes, Yemarshet K. Guillén, Maria Jose Avilés, Pablo M. Debiec-Rychter, Maria Sciot, Raf Schöffski, Patrick |
author_sort | Wang, Yannick |
collection | PubMed |
description | The majority of patients with gastrointestinal stromal tumors (GIST) eventually become resistant with time due to secondary mutations in the driver receptor tyrosine kinase. Novel treatments that do not target these receptors may therefore be preferable. For the first time, we evaluated a tubulin inhibitor, plocabulin, in patient-derived xenograft (PDX) models of GIST, a disease generally considered to be resistant to cytotoxic agents. Three PDX models of GIST with different KIT genotype were generated by implanting tumor fragments from patients directly into nude mice. We then used these well characterized models with distinct sensitivity to imatinib to evaluate the efficacy of the novel tubulin inhibitor. The efficacy of the drug was assessed by volumetric analysis of the tumors, histopathology, immunohistochemistry and Western blotting. Plocabulin treatment led to extensive necrosis in all three models and significant tumor shrinkage in two models. This histological response can be explained by the drug's vascular-disruptive properties, which resulted in a shutdown of tumor vasculature, reflected by a decreased total vascular area in the tumor tissue. Our results demonstrated the in vivo efficacy of the novel tubulin inhibitor plocabulin in PDX models of GIST and challenge the established view that GIST are resistant to cytotoxic agents in general and to tubulin inhibitors in particular. Our findings provide a convincing rationale for early clinical exploration of plocabulin in GIST and warrant further exploration of this class of drugs in the management of this common sarcoma subtype. |
format | Online Article Text |
id | pubmed-7381700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-73817002020-07-28 Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors Wang, Yannick Wozniak, Agnieszka Wellens, Jasmien Gebreyohannes, Yemarshet K. Guillén, Maria Jose Avilés, Pablo M. Debiec-Rychter, Maria Sciot, Raf Schöffski, Patrick Transl Oncol Original article The majority of patients with gastrointestinal stromal tumors (GIST) eventually become resistant with time due to secondary mutations in the driver receptor tyrosine kinase. Novel treatments that do not target these receptors may therefore be preferable. For the first time, we evaluated a tubulin inhibitor, plocabulin, in patient-derived xenograft (PDX) models of GIST, a disease generally considered to be resistant to cytotoxic agents. Three PDX models of GIST with different KIT genotype were generated by implanting tumor fragments from patients directly into nude mice. We then used these well characterized models with distinct sensitivity to imatinib to evaluate the efficacy of the novel tubulin inhibitor. The efficacy of the drug was assessed by volumetric analysis of the tumors, histopathology, immunohistochemistry and Western blotting. Plocabulin treatment led to extensive necrosis in all three models and significant tumor shrinkage in two models. This histological response can be explained by the drug's vascular-disruptive properties, which resulted in a shutdown of tumor vasculature, reflected by a decreased total vascular area in the tumor tissue. Our results demonstrated the in vivo efficacy of the novel tubulin inhibitor plocabulin in PDX models of GIST and challenge the established view that GIST are resistant to cytotoxic agents in general and to tubulin inhibitors in particular. Our findings provide a convincing rationale for early clinical exploration of plocabulin in GIST and warrant further exploration of this class of drugs in the management of this common sarcoma subtype. Neoplasia Press 2020-07-22 /pmc/articles/PMC7381700/ /pubmed/32711367 http://dx.doi.org/10.1016/j.tranon.2020.100832 Text en © 2020 Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original article Wang, Yannick Wozniak, Agnieszka Wellens, Jasmien Gebreyohannes, Yemarshet K. Guillén, Maria Jose Avilés, Pablo M. Debiec-Rychter, Maria Sciot, Raf Schöffski, Patrick Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors |
title | Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors |
title_full | Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors |
title_fullStr | Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors |
title_full_unstemmed | Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors |
title_short | Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors |
title_sort | plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors |
topic | Original article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381700/ https://www.ncbi.nlm.nih.gov/pubmed/32711367 http://dx.doi.org/10.1016/j.tranon.2020.100832 |
work_keys_str_mv | AT wangyannick plocabulinanoveltubulininhibitorhaspotentantitumoractivityinpatientderivedxenograftmodelsofgastrointestinalstromaltumors AT wozniakagnieszka plocabulinanoveltubulininhibitorhaspotentantitumoractivityinpatientderivedxenograftmodelsofgastrointestinalstromaltumors AT wellensjasmien plocabulinanoveltubulininhibitorhaspotentantitumoractivityinpatientderivedxenograftmodelsofgastrointestinalstromaltumors AT gebreyohannesyemarshetk plocabulinanoveltubulininhibitorhaspotentantitumoractivityinpatientderivedxenograftmodelsofgastrointestinalstromaltumors AT guillenmariajose plocabulinanoveltubulininhibitorhaspotentantitumoractivityinpatientderivedxenograftmodelsofgastrointestinalstromaltumors AT avilespablom plocabulinanoveltubulininhibitorhaspotentantitumoractivityinpatientderivedxenograftmodelsofgastrointestinalstromaltumors AT debiecrychtermaria plocabulinanoveltubulininhibitorhaspotentantitumoractivityinpatientderivedxenograftmodelsofgastrointestinalstromaltumors AT sciotraf plocabulinanoveltubulininhibitorhaspotentantitumoractivityinpatientderivedxenograftmodelsofgastrointestinalstromaltumors AT schoffskipatrick plocabulinanoveltubulininhibitorhaspotentantitumoractivityinpatientderivedxenograftmodelsofgastrointestinalstromaltumors |